KRAS and familial pancreatic carcinoma: A phase II clinical study did not show a difference in response between KRAS mutation and WT pancreatic cancers [35], although this being an experimental compound, this lack of difference could be as a result of lack of efficacy generally; to our knowledge, the effect of APC mutation on RDEA119 sensitivity has not been studied.